PDX Model Market Size, Growth, Share & Trends Analysis
Patient Derived Xenografts/PDX Models Market by Type (Mouse, Rat), Service (Model Creation, Characterization), Implantation Method (Subcutaneous), Tumor Type (Respiratory, GI, Gynecological), Application (Preclinical, Biomarker) - Global Forecast to 2030
USD 0.66 BN
MARKET SIZE, 2030
CAGR 12.5%
(2025-2030)
264
REPORT PAGES
261
MARKET TABLES
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global PDX model market is projected to reach USD 0.66 billion by 2030 from USD 0.37 billion in 2025, at a CAGR of 12.5% during the forecast period of 2025-2030. The major factors driving the growth in the PDX model market include the rising demand for clinically relevant preclinical models that closely replicate human tumor biology and therapeutic response. Additionally, growth in the PDX model market is being supported by the increasing focus on personalized oncology, expansion of immuno-oncology and targeted therapy research, and the integration of humanized and omics-based PDX platforms that enhance translational predictivity.
KEY TAKEAWAYS
-
BY REGIONNorth America accounted for the largest share of 53.3% in 2024, driven by the strong pharmaceutical R&D investments, advanced research infrastructure, and widespread adoption of PDX models.
-
BY IMPLANTATION METHODSubcutaneous implantation dominates the market due to its improved clinical relevance, cost-effectiveness, and ease of monitoring.
-
BY TYPEMouse models accounted for the largest share of the market due to the increasing demand for personalized cancer treatments, efficient drug development, and reduced traditional animal testing.
-
BY APPLICATIONThe preclinical drug development segment currently dominate the market, supported by the improved drug development efficiency and the discovery of predictive biomarkers.
-
BY TUMOR TYPERespiratory tumor models are expected to register the highest CAGR of 11.3% during the forecast period.
-
BY END USERPharmaceutical & biotechnology companies held the largest market share of 56.2% in 2024, supported by the extensive use of PDX in drug discovery, efficacy testing, and biomarker validation.
-
COMPETITIVE LANDSCAPEThe major market players have adopted organic and inorganic strategies, including product launches, expansions, partnerships, and acquisitions. For instance, Crown Bioscience announced the opening of a new site in Singapore to expand the company’s capacity to support global and local biotech and pharma companies engaged in pre-clinical and translational oncology drug discovery and development.
The PDX model market is projected to witness substantial growth over the next decade, driven by factors such as the rising demand for clinically relevant preclinical models, the increasing focus on personalized and precision oncology, and the expansion of immuno-oncology and targeted therapy research. Furthermore, advancements in humanized and omics-integrated PDX platforms, along with growing collaborations between pharmaceutical companies and CROs, are expected to further accelerate market growth in the coming years.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The patient-derived xenograft (PDX) models market is witnessing a significant transition from traditional mouse and rat models toward humanized and multi-omics-integrated PDX platforms. This shift is driven by growing adoption among pharmaceutical and biotechnology companies, contract research organizations (CROs), and academic institutes seeking improved translational relevance. Key imperatives such as expansion of humanized PDX models, integration of AI and omics technologies, and development of scalable, standardized workflows are enabling faster oncology drug development, enhanced biomarker validation, and reduced late-stage failures. Collectively, these advancements are optimizing precision medicine outcomes and accelerating the clinical success of novel therapeutics.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
Level
-
Growing demand for personalized medicine
-
Rising investments in cancer research
RESTRAINTS
Impact
Level
Level
-
Discontinuation of animal models for clinical trials by FDA
OPPORTUNITIES
Impact
Level
Level
-
Emergence of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) in biomedical research
CHALLENGES
Impact
Level
Level
-
Development of alternative animal testing methods
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Growing demand for personalized medicine
The rising focus on personalized medicine is driving the adoption of PDX models, as they closely mimic patient-specific tumor biology and therapeutic responses. These models enable researchers to evaluate individualized treatment strategies, optimize drug selection, and improve clinical outcomes, thereby enhancing translational relevance in oncology drug development.
Restraint: Discontinuation of animal models for clinical trials by FDA
The FDA’s gradual move toward minimizing animal use in clinical testing poses a restraint for the PDX model market. This regulatory shift may limit the adoption of models for certain preclinical applications, prompting stakeholders to seek alternative, non-animal systems and adopt advanced in vitro or computational modeling approaches.
Opportunity: Emergence of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) in biomedical research
The integration of CRISPR technology with PDX models presents a major opportunity for precision oncology research. CRISPR-enhanced PDX systems allow targeted gene editing, facilitating the study of tumor genetics, drug resistance mechanisms, and novel therapeutic targets, thereby expanding the scope and efficiency of cancer model-based research.
Challenge: Development of alternative animal testing methods
The increasing push for alternative testing approaches, such as organoids, organ-on-chip systems, and AI-driven simulations, challenges the PDX model market. These emerging technologies offer ethical and cost-efficient solutions, compelling researchers to balance traditional PDX strengths with innovative, non-animal preclinical testing methods.
PDX Models Market: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Collaboration of Hsieh Lab with PDX Core to develop PDX lines from bladder cancer patients, validate them, then use them to identify therapeutic vulnerabilities (e.g., translation inhibitors) and organoid lines derived from PDX. | Enables academic research to rapidly test mechanistic hypotheses in clinically-derived models, speeds up discovery of therapeutic targets and supports publication/funding outcomes. |
 |
Employs TumorGraft PDX models across multiple cancer types to evaluate targeted therapies and combination regimens for efficacy and resistance mechanisms. | Enhances therapeutic decision-making, validates drug response profiles, and reduces clinical attrition risk. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The patient-derived xenograft (PDX) models market ecosystem comprises raw material suppliers (Crown Bioscience, Taconic Biosciences), product manufacturers (The Jackson Laboratory, Hera Biolabs), regulatory bodies (US Food and Drug Administration, European Medicines Agency), and end users (AstraZeneca, University of Cambridge). Raw material suppliers provide animal models, tissues, and essential biological components for xenograft establishment, while product manufacturers develop and supply validated PDX models and associated research tools. Regulatory bodies ensure ethical compliance and standardization across preclinical studies. End users, including pharmaceutical and biotechnology companies as well as academic institutes, utilize PDX models for oncology drug discovery, efficacy testing, and translational research. Collaboration among stakeholders fosters innovation, model refinement, and accelerated progress toward precision oncology solutions.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
PDX Model Market, By Implantation Method
In 2024, the subcutaneous implantation segment accounted for the largest share of the PDX model market. Factors such as procedural simplicity, high tumor engraftment rates, reproducibility, and suitability for evaluating drug efficacy are expected to drive market growth.
PDX Model Market, By Type
In 2024, the mouse model segment accounted for the largest share of the PDX model market. Genetic similarity to humans, ease of handling, cost-effectiveness, and well-established tumor engraftment. has driven interest in the mouse model segment and supported market growth.
PDX Model Market, By Application
In 2024, the preclinical drug development segment accounted for the largest share of the PDX model market. The extensive PDX use in efficacy testing, safety evaluation, biomarker discovery, and translational oncology research drives strong demand in this segment.
REGION
Asia Pacific to be fastest-growing region in global PDX model market during forecast period
The Asia Pacific PDX model market is expected to register the highest CAGR during the forecast period, primarily due to the expanding pharmaceutical and biotechnology sectors, rising investments in oncology research, increasing collaborations between CROs and academic institutes, and the growing availability of humanized animal models and advanced research infrastructure across the region.
PDX Models Market: COMPANY EVALUATION MATRIX
The Jackson Laboratory (Star) leads the patient-derived xenograft (PDX) model market with a comprehensive portfolio of clinically validated tumor models and humanized mouse platforms that deliver high translational accuracy in oncology research. Its extensive biobank of annotated PDX models, strong expertise in model standardization, and strategic collaborations with global pharmaceutical and biotechnology companies have reinforced its leadership in preclinical drug discovery and precision medicine. Hera Biolabs (Emerging Leader) is rapidly strengthening its market presence through innovative gene-edited PDX systems, including its proprietary OncoRat platform, which enhances predictivity in efficacy and toxicity assessment. By leveraging CRISPR-based model development, expanding humanized model offerings, and pursuing strategic partnerships, Hera Biolabs is well-positioned to transition toward the leaders’ quadrant as demand for next-generation, high-fidelity preclinical models continues to grow.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- JSR Corporation (Japan)
- WuXi AppTec (China)
- The Jackson Laboratory (US)
- Charles River Laboratories (US)
- Taconic Biosciences, Inc. (US)
- Oncodesign Precision Medicine (France)
- Inotiv (US)
- Pharmatest Services (Finland)
- Hera Biolabs (US)
- EPO Berlin-Buch GmbH (Germany)
- XenTech (France)
- Urosphere (France)
- Altogen Labs (US)
- Abnova Corporation (Taiwan)
- Genesis Biotechnology Group (US)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USD 0.32 Billion |
| Market Forecast in 2030 (Value) | USD 0.66 Billion |
| Growth Rate | CAGR of 12.5% from 2025 to 2030 |
| Years Considered | 2023–2030 |
| Base Year | 2024 |
| Forecast Period | 2025–2030 |
| Units Considered | Value (USD Million/Billion) |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
|
| Regions Covered | North America, Asia Pacific, Europe, Latin America, Middle East & Africa |
WHAT IS IN IT FOR YOU: PDX Models Market REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Rest of Europe Breakdown | Country-level market sizing and growth forecasts (Sweden, Switzerland, Turkey, the Netherlands, Norway, Poland, Portugal, Romania, Denmark, Estonia, Finland, the Czech Republic, Greece, Austria, Belgium, and Russia) | Provides granular country-level insights, enabling clients to prioritize high-growth markets, and tailor portfolio strategies across products for maximum regional impact |
| Company Evaluation |
|
Delivers visibility into competitors, helping clients identify partners, evaluate positioning, and detect market gaps for smarter collaboration, outsourcing, and strategic market entry decisions |
RECENT DEVELOPMENTS
- May 2024 : Crown Bioscience announced a global collaboration with Shanghai Model Organisms Center (SMOC) to enhance its immuno-oncology and PDX model capabilities. The five-year agreement grants Crown access to SMOC’s extensive library of genetically engineered mouse models, including over 6,000 off-the-shelf models and 11,000 prototypes for global deployment across Crown’s facilities. The deal is designed to strengthen Crown’s translational model offerings, standardize supply chain and licensing globally, and accelerate oncology research partnerships.
- May 2023 : Crown Bioscience announced the opening of a new site in Singapore to expand the company’s capacity to support global and local biotech and pharma companies engaged in pre-clinical and translational oncology drug discovery and development.
- September 2022 : Crown Bioscience & MBL, a joint venture between two JSR Life Sciences companies, announced the launch of their full-service drug discovery and development services in Japan. Organoids and high-content imaging technologies are available services of the company, alongside Crown’s PDX collection of ~3,000 models.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
35
2
EXECUTIVE SUMMARY
40
3
PREMIUM INSIGHTS
46
4
MARKET OVERVIEW
Uncover emerging market dynamics driving growth and innovation in the industry landscape.
49
5
INDUSTRY TRENDS
Navigate competitive dynamics and pricing shifts in the patient-derived xenograft models market.
56
5.1
PORTER’S FIVE FORCES ANALYSIS
5.1.1
THREAT OF NEW ENTRANTS
5.1.2
THREAT OF SUBSTITUTES
5.1.3
BARGAINING POWER OF BUYERS
5.1.4
BARGAINING POWER OF SUPPLIERS
5.1.5
INTENSITY OF COMPETITIVE RIVALRY
5.2
ECOSYSTEM ANALYSIS
5.3
VALUE CHAIN ANALYSIS
5.4
PRICING ANALYSIS
5.4.1
AVERAGE SELLING PRICE TREND OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS, BY KEY PLAYER, 2022−2024
5.4.2
AVERAGE SELLING PRICE TREND OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS, BY IMPLANTATION METHOD, 2022−2024
5.4.3
AVERAGE SELLING PRICE TREND OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS, BY TUMOR TYPE, 2022−2024
5.4.4
AVERAGE SELLING PRICE OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS, BY REGION, 2024
5.5
TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.6
PATENT ANALYSIS
5.6.1
METHODOLOGY
5.6.2
NUMBER OF PATENTS FILED, BY DOCUMENT TYPE
5.6.3
LIST OF KEY PATENTS
5.7
TRADE DATA ANALYSIS
5.7.1
IMPORT DATA FOR HS CODE 106.19.90, 2020–2024
5.7.2
EXPORT DATA FOR HS CODE 106.19.90, 2020–2024
5.8
IMPACT OF 2025 US TARIFF ON PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET
5.8.1
KEY TARIFF RATES
5.8.2
PRICE IMPACT ANALYSIS
5.8.3
KEY IMPACT ON VARIOUS REGIONS
5.8.3.1
NORTH AMERICA
5.8.3.2
EUROPE
5.8.3.3
ASIA PACIFIC
5.8.3.4
REST OF THE WORLD
5.8.4
IMPACT ON END-USE INDUSTRIES
5.8.4.1
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
5.8.4.2
CROS & CDMOS
5.8.4.3
ACADEMIC & RESEARCH INSTITUTES
5.9
MACROECONOMIC OUTLOOK
5.9.1
INTRODUCTION
5.9.2
GDP TRENDS AND FORECAST
5.9.3
R&D TRENDS IN GLOBAL HEALTHCARE INDUSTRY
5.9.4
R&D TRENDS IN GLOBAL PHARMA INDUSTRY
5.10
KEY CONFERENCES & EVENTS, 2025–2026
5.11
INVESTMENT & FUNDING SCENARIO
5.11.1
VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE
5.12
CASE STUDY ANALYSIS
5.12.1
IMAGING-READY ORTHOTOPIC PDX FOR PEDIATRIC BRAIN TUMORS
5.12.2
HOST-STRAIN SELECTION USING BREAST CANCER PDX
5.12.3
RESISTANCE-ANCHORED PDX PANEL TO DESIGN MOUSE CLINICAL TRIAL
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
AI-driven innovations revolutionize PDX models, enhancing precision medicine with cutting-edge gene editing and multi-omics.
78
6.1
KEY EMERGING TECHNOLOGIES
6.1.1
NEXT-GENERATION SEQUENCING
6.1.2
GENE EDITING
6.2
COMPLEMENTARY TECHNOLOGIES
6.2.1
MULTI-OMICS
6.2.2
MULTI-MODEL PRECLINICAL IMAGING
6.3
TECHNOLOGY ROADMAP
6.4
FUTURE APPLICATIONS
6.5
IMPACT OF AI/GEN AI ON PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET
6.5.1
TOP USE CASES & MARKET POTENTIAL
6.5.2
CASE STUDIES OF AI IMPLEMENTATION
6.5.3
BEST PRACTICES IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS CREATION
6.5.4
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET
6.5.5
HIGH READINESS VS. ADOPTION BARRIERS
7
SUSTAINABILITY AND REGULATORY LANDSCAPE
Navigate global sustainability regulations to ensure compliance and leverage eco-standards for competitive advantage.
84
7.1
REGIONAL REGULATIONS & COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2
INDUSTRY STANDARDS
7.1.2.1
NORTH AMERICA
7.1.2.2
EUROPE
7.1.2.3
ASIA PACIFIC
7.1.2.4
LATIN AMERICA
7.2
SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
7.3
CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
Understand the complexities of buyer decisions and identify untapped opportunities in unmet industry needs.
94
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM END-USE INDUSTRIES
9
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 59 Data Tables
98
9.1
INTRODUCTION
9.2
PDX MODELS
9.2.1
MOUSE MODEL
9.2.1.1
PROVEN EFFICACY OF MOUSE MODEL IN CANCER RESEARCH AND DRUG DEVELOPMENT TO BOOST SEGMENT GROWTH
9.2.2
RAT MODEL
9.2.2.1
EMERGENCE OF ADVANCED TECHNOLOGIES IN PDX RAT MODELS TO AID MARKET GROWTH
9.3
SERVICES
9.3.1
MODEL CREATION & EXPANISON SERVICES
9.3.1.1
NEED FOR FASTER PASSAGING OF MODELS TO TO BUILD STUDY-READY COHORTS (P1–P3) TO BOOST SEGMENT GROWTH
9.3.2
MODEL CHARACTERIZATION SERVICES
9.3.2.1
GROWING DEMAND FOR BIOMARKER ANALYSIS TO DRIVE SEGMENT GROWTH
9.3.3
CRYOPRESERVATION SERVICES
9.3.3.1
RELIABLE AND LOW-PASSAGE BIOBANKING SERVICES TO OFFER GROWTH OPPORTUNITIES
9.3.4
OTHER PDX SERVICES
10
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 22 Data Tables
123
10.1
INTRODUCTION
10.2
SUBCUTANEOUS IMPLANTATION
10.2.1
STANDARDIZED AND SCALABLE PDX MODEL EXPANSION TO DRIVE SEGMENT GROWTH
10.3
ORTHOTOPIC IMPLANTATION
10.3.1
DEMAND FOR CLINICALLY RELEVANT AND SITE-SPECIFIC PDX MODELS TO BOOST SEGMENT GROWTH
10.4
OTHER IMPLANTATION METHODS
11
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 43 Data Tables
136
11.1
INTRODUCTION
11.2
GASTROINTESTINAL TUMOR MODEL
11.2.1
HIGH TISSUE AVAILABILITY AND STANDARDIZED ENGRAFTMENT PROTOCOLS TO FUEL MARKET GROWTH
11.3
GYNECOLOGICAL TUMOR MODEL
11.3.1
EXPANDING ORTHOTOPIC AND HUMANIZED PDX APPLICATIONS TO DRIVE MARKET
11.4
RESPIRATORY TUMOR MODEL
11.4.1
INCREASING ADOPTION OF ORTHOTOPIC AND HUMANIZED MODELS TO BOOST SEGMENT GROWTH
11.5
UROLOGICAL TUMOR MODEL
11.5.1
EXPANSION OF HORMONE-CONTEXT AND IMMUNE-COMPETENT MODELS TO FAVOR MARKET ADOPTION
11.6
HEMATOLOGICAL TUMOR MODEL
11.6.1
RISING ADOPTION OF HUMANIZED AND RELAPSE-DERIVED MODELS TO DRIVE SEGMENT GROWTH
11.7
OTHER TUMOR MODELS
12
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 29 Data Tables
157
12.1
INTRODUCTION
12.2
PRECLINICAL RESEARCH
12.2.1
HIGH IMPORTANCE FOR PDX IN EFFICACY CONFIRMATION TO DRIVE MARKET
12.3
BIOMARKER ANALYSIS
12.3.1
DEMAND FOR MULTI-OMICS TO AUGMENT MARKET GROWTH
12.4
TRANSLATIONAL RESEARCH
12.4.1
DEMAND FOR PDX MODELS IN CO-CLINICAL TRIAL DESIGNS TO BOOST SEGMENT GROWTH
12.5
BIOBANKING
12.5.1
DEMAND FOR PDX MODELS IN SPECIALIZED BANKS TO SPUR MARKET GROWTH
13
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Million | 22 Data Tables
171
13.1
INTRODUCTION
13.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
13.2.1
INTEGRATION OF TRANSLATIONALLY RELEVANT PDX WORKFLOWS TO DRIVE MARKET GROWTH
13.3
CROS & CDMOS
13.3.1
EXPANDED OUTSOURCING THROUGH INTEGRATED WORKFLOWS TO FUEL MARKET GROWTH
13.4
ACADEMIC & RESEARCH INSTITUTES
13.4.1
ENHANCED INSTITUTIONAL BIOBANKS AND MULTI-OMIC PROFILING TO AUGMENT MARKET GROWTH
14
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 16 Countries | 202 Data Tables.
182
14.1
INTRODUCTION
14.2
NORTH AMERICA
14.2.1
US
14.2.1.1
US TO DOMINATE NORTH AMERICAN PDX MODELS MARKET DURING STUDY PERIOD
14.2.2
CANADA
14.2.2.1
GROWTH RESEARCH AND ACADEMIC ACTIVITIES ON ONCOLOGY TO FUEL MARKET GROWTH
14.3
EUROPE
14.3.1
GERMANY
14.3.1.1
GROWTH IN BIOTECHNOLOGY INDUSTRY AND STRONG PHARMA PRESENCE TO SPUR MARKET GROWTH
14.3.2
UK
14.3.2.1
INCREASING FOCUS ON CANCER RESEARCH TO PROPEL MARKET
14.3.3
FRANCE
14.3.3.1
ROBUST RESEARCH ACTIVITIES IN IMMUNE-ONCOLOGY TO DRIVE MARKET GROWTH
14.3.4
ITALY
14.3.4.1
GROWING PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY AND INCREASING FOCUS ON RADIOPHARMACEUTICALS TO FAVOR MARKET GROWTH
14.3.5
SPAIN
14.3.5.1
INCREASING TRANSLATIONAL ACTIVITIES TO BOOST MARKET GROWTH
14.3.6
REST OF EUROPE
14.4
ASIA PACIFIC
14.4.1
CHINA
14.4.1.1
FAVORABLE INVESTMENTS IN LIFE SCIENCES RESEARCH TO DRIVE MARKET
14.4.2
JAPAN
14.4.2.1
INCREASING FOCUS ON PERSONALIZED DIAGNOSTICS PRODUCTS TO DRIVE MARKET
14.4.3
INDIA
14.4.3.1
FAVORABLE INITIATIVES FOR DRUG DISCOVERY & DEVELOPMENT TO BOOST MARKET GROWTH
14.4.4
AUSTRALIA
14.4.4.1
HIGH NUMBER OF RESEARCH INSTITUTES TO FAVOR MARKET GROWTH
14.4.5
SOUTH KOREA
14.4.5.1
INNOVATION IN HEALTH AND BIOTECH SECTORS TO SUPPORT MARKET UPTAKE
14.4.6
REST OF ASIA PACIFIC
14.5
LATIN AMERICA
14.5.1
BRAZIL
14.5.1.1
INCREASING INVESTMENTS IN BIOPHARMACEUTICAL RESEARCH TO FUEL UPTAKE
14.5.2
MEXICO
14.5.2.1
EXPANDING HEALTHCARE ECOSYSTEM TO SUPPORT MARKET GROWTH
14.5.3
REST OF LATIN AMERICA
14.6
MIDDLE EAST
14.6.1
GCC COUNTRIES
14.6.1.1
KINGDOM OF SAUDI ARABIA
14.6.1.2
UAE
14.6.1.3
REST OF GCC COUNTRIES
14.6.2
REST OF MIDDLE EAST
14.7
AFRICA
14.7.1
INCREASING FOCUS ON PRECISION MEDICINE INITIATIVES TO SUPPORT MARKET GROWTH
15
COMPETITIVE LANDSCAPE
Discover key player strategies reshaping the PDX market landscape and their competitive advantage.
271
15.1
INTRODUCTION
15.2
KEY PLAYERS STRATEGIES/RIGHT TO WIN
15.2.1
STRATEGIES ADOPTED BY KEY PLAYERS IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, 2022–2025
15.3
REVENUE ANALYSIS, 2022–2024
15.4
MARKET SHARE ANALYSIS, 2024
15.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
15.5.1
STARS
15.5.2
EMERGING LEADERS
15.5.3
PERVASIVE PLAYERS
15.5.4
PARTICIPANTS
15.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
15.5.5.1
COMPANY FOOTPRINT
15.5.5.2
REGION FOOTPRINT
15.5.5.3
MODEL TYPE & SERVICE FOOTPRINT
15.5.5.4
TUMOR TYPE FOOTPRINT
15.5.5.5
IMPLANTATION METHOD FOOTPRINT
15.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
15.6.1
PROGRESSIVE COMPANIES
15.6.2
RESPONSIVE COMPANIES
15.6.3
DYNAMIC COMPANIES
15.6.4
STARTING BLOCKS
15.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SME PLAYERS, 2024
15.6.5.1
DETAILED LIST OF KEY STARTUPS/SMES
15.6.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
15.7
COMPANY VALUATION & FINANCIAL METRICS
15.7.1
FINANCIAL METRICS
15.7.2
COMPANY VALUATION
15.8
BRAND/PRODUCT COMPARISON
15.9
COMPETITIVE SCENARIO
15.9.1
DEALS
15.9.2
EXPANSIONS
16
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
291
16.1
KEY PLAYERS
16.1.1
CHARLES RIVER LABORATORIES
16.1.1.1
BUSINESS OVERVIEW
16.1.1.2
PRODUCTS/SERVICES OFFERED
16.1.1.3
RECENT DEVELOPMENTS
16.1.1.4
MNM VIEW
16.1.2
THE JACKSON LABORATORY
16.1.3
INOTIV
16.1.4
JSR CORPORATION
16.1.5
GENOWAY
16.1.6
WUXI APPTEC + WUXI BIOLOGICS
16.1.7
BIOCYTOGEN PHARMACEUTICALS CO., LTD.
16.1.8
TACONIC BIOSCIENCES, INC.
16.1.9
ONCODESIGN SERVICES (ONCODESIGN PRECISION MEDICINE)
16.1.10
CHAMPIONS ONCOLOGY, INC.
16.1.11
PHARMARON
16.1.12
SYNGENE INTERNATIONAL LIMITED
16.1.13
LABCORP
16.1.14
EUROFINS SCIENTIFIC
16.1.15
VITALSTAR BIOTECHNOLOGY CO., LTD.
16.2
OTHER PLAYERS
16.2.1
CREATIVE ANIMODEL
16.2.2
JOINN LABORATORIES (CHINA) CO., LTD.
16.2.3
CREATIVE BIOLABS
16.2.4
ARAGEN LIFE SCIENCES LTD.
16.2.5
PHARMTEST SERVICES
16.2.6
LIDE SHANGHAI BIOTECH CO., LTD.
16.2.7
CERTIS ONCOLOGY SOLUTIONS
16.2.8
INNOSER
16.2.9
SHANGHAI CHEMPARTNER
16.2.10
IVRS AB
17
RESEARCH METHODOLOGY
348
17.1
RESEARCH DATA
17.1.1
SECONDARY DATA
17.1.2
KEY OBJECTIVES OF SECONDARY RESEARCH
17.1.3
PRIMARY DATA
17.2
MARKET ESTIMATION METHODOLOGY
17.2.1
COMPANY REVENUE ANALYSIS: BOTTOM-UP APPROACH
17.2.2
INSIGHTS FROM PRIMARY EXPERTS
17.2.3
TOP-DOWN APPROACH
17.3
GROWTH FORECAST
17.4
DATA TRIANGULATION
17.5
STUDY ASSUMPTIONS
17.6
RESEARCH LIMITATIONS
17.7
MARKET FORECAST
17.8
RISK ANALYSIS
18
APPENDIX
359
18.1
DISCUSSION GUIDE
18.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
18.3
CUSTOMIZATION OPTIONS
18.4
RELATED REPORTS
18.5
AUTHOR DETAILS
LIST OF TABLES
TABLE 1
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: IMPACT OF PORTER’S FIVE FORCES
TABLE 3
AVERAGE SELLING PRICE TREND OF PATIENT-DERIVED XENOGRAFT (PDX) MODEL TYPES, BY KEY PLAYER, 2022−2024
TABLE 4
AVERAGE SELLING PRICE TREND OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS, BY IMPLANTATION METHOD, 2022−2024
TABLE 5
AVERAGE SELLING PRICE TREND OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS, BY TUMOR TYPE, 2022−2024
TABLE 6
AVERAGE SELLING PRICE OF PATIENT-DERIVED XENOGRAFT (PDX) MODEL TYPES, BY REGION, 2024
TABLE 7
NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014–2024
TABLE 8
LIST OF KEY PATENTS IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, 2023–2025
TABLE 9
IMPORT DATA FOR HS CODE 106.19.90, 2020–2024 (USD THOUSAND)
TABLE 10
EXPORT DATA FOR HS CODE 106.19.90, 2020–2024 (USD THOUSAND)
TABLE 11
US-AJUSTED RECIPROCAL TARIFF RATES
TABLE 12
KEY PRODUCT-RELATED TARIFF: LIVE ANIMALS, PRODUCT OF ANIMAL ORIGIN, MISCELLANEOUS CHEMICAL PRODUCTS
TABLE 13
CRITICAL COMPONENTS EXPOSED TO TARIFF CHANGES
TABLE 14
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026
TABLE 15
INVESTMENT & FUNDING ACTIVITY IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY KEY PLAYER, 2022−2025
TABLE 16
CASE STUDIES OF AI IMPLEMENTATION IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET
TABLE 17
HIGH READINESS VS. ADOPTION BARRIERS IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET
TABLE 18
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22
VENDOR CERTIFICATIONS IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET
TABLE 23
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)
TABLE 24
PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 25
PDX MODELS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 26
NORTH AMERICA: PDX MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 27
EUROPE: PDX MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 28
ASIA PACIFIC: PDX MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 29
LATIN AMERICA: PDX MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 30
MIDDLE EAST: PDX MODELS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 31
GCC COUNTRIES: PDX MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 32
MOUSE MODEL MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 33
NORTH AMERICA: MOUSE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 34
EUROPE: MOUSE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 35
ASIA PACIFIC: MOUSE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 36
LATIN AMERICA: MOUSE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 37
MIDDLE EAST: MOUSE MODEL MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 38
GCC COUNTRIES: MOUSE MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 39
RAT MODEL MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 40
NORTH AMERICA: RAT MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 41
EUROPE: RAT MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 42
ASIA PACIFIC: RAT MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 43
LATIN AMERICA: RAT MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 44
MIDDLE EAST: RAT MODEL MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 45
GCC COUNTRIES: RAT MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 46
PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 47
PDX SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 48
NORTH AMERICA: PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 49
EUROPE: PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 50
ASIA PACIFIC: PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 51
LATIN AMERICA: PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 52
MIDDLE EAST: PDX SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 53
GCC COUNTRIES: PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 54
MODEL CREATION & EXPANSION SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 55
NORTH AMERICA: MODEL CREATION & EXPANSION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 56
EUROPE: MODEL CREATION & EXPANSION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 57
ASIA PACIFIC: MODEL CREATION & EXPANSION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 58
LATIN AMERICA: MODEL CREATION & EXPANSION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 59
MIDDLE EAST: MODEL CREATION & EXPANSION SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 60
GCC COUNTRIES: MODEL CREATION & EXPANSION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 61
MODEL CHARATERIZATION SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 62
NORTH AMERICA: MODEL CHARATERIZATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 63
EUROPE: MODEL CHARATERIZATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 64
ASIA PACIFIC: MODEL CHARATERIZATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 65
LATIN AMERICA: MODEL CHARATERIZATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 66
MIDDLE EAST: MODEL CHARATERIZATION SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 67
GCC COUNTRIES: MODEL CHARATERIZATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 68
CRYOPRESERVATION SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 69
NORTH AMERICA: CRYOPRESERVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 70
EUROPE: CRYOPRESERVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 71
ASIA PACIFIC: CRYOPRESERVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 72
LATIN AMERICA: CRYOPRESERVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 73
MIDDLE EAST: CRYOPRESERVATION SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 74
GCC COUNTRIES: CRYOPRESERVATION SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 75
OTHER PDX SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 76
NORTH AMERICA: OTHER PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 77
EUROPE: OTHER PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 78
ASIA PACIFIC: OTHER PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 79
LATIN AMERICA: OTHER PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 80
MIDDLE EAST: OTHER PDX SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 81
GCC COUNTRIES: OTHER PDX SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 82
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION)
TABLE 83
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR SUBCUTANEOUS IMPLANTATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 84
NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR SUBCUTANEOUS IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 85
EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR SUBCUTANEOUS IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 86
ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR SUBCUTANEOUS IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 87
LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR SUBCUTANEOUS IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 88
MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR SUBCUTANEOUS IMPLANTATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 89
GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR SUBCUTANEOUS IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 90
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ORTHOTOPIC IMPLANTATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 91
NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ORTHOTOPIC IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 92
EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ORTHOTOPIC IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 93
ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ORTHOTOPIC IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 94
LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ORTHOTOPIC IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 95
MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ORTHOTOPIC IMPLANTATION, BY REGION, 2023–2030 (USD MILLION)
TABLE 96
GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ORTHOTOPIC IMPLANTATION, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 97
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER IMPLANTATION METHODS, BY REGION, 2023–2030 (USD MILLION)
TABLE 98
NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER IMPLANTATION METHODS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 99
EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER IMPLANTATION METHODS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 100
ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER IMPLANTATION METHODS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 101
LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER IMPLANTATION METHODS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 102
MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER IMPLANTATION METHODS, BY REGION, 2023–2030 (USD MILLION)
TABLE 103
GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER IMPLANTATION METHODS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 104
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION)
TABLE 105
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GASTROINTESTINAL TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION)
TABLE 106
NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GASTROINTESTINAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 107
EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GASTROINTESTINAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 108
ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GASTROINTESTINAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 109
LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GASTROINTESTINAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 110
MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GASTROINTESTINAL TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION)
TABLE 111
GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GASTROINTESTINAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 112
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GYNECOLOGICAL TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION)
TABLE 113
NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GYNECOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 114
EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GYNECOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 115
ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GYNECOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 116
LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GYNECOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 117
MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GYNECOLOGICAL TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION)
TABLE 118
GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR GYNECOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 119
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR RESPIRATORY TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION)
TABLE 120
NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR RESPIRATORY TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 121
EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR RESPIRATORY TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 122
ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR RESPIRATORY TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 123
LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR RESPIRATORY TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 124
MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR RESPIRATORY TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION)
TABLE 125
GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR RESPIRATORY TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 126
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR UROLOGICAL TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION)
TABLE 127
NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR UROLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 128
EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR UROLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 129
ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR UROLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 130
LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR UROLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 131
MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR UROLOGICAL TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION)
TABLE 132
GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR UROLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 133
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR HEMATOLOGICAL TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION)
TABLE 134
NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR HEMATOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 135
EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR HEMATOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 136
ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR HEMATOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 137
LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR HEMATOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 138
MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR HEMATOLOGICAL TUMOR MODEL, BY REGION, 2023–2030 (USD MILLION)
TABLE 139
GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR HEMATOLOGICAL TUMOR MODEL, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 140
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER TUMOR MODELS, BY REGION, 2023–2030 (USD MILLION)
TABLE 141
NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER TUMOR MODELS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 142
EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER TUMOR MODELS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 143
ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER TUMOR MODELS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 144
LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER TUMOR MODELS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 145
MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER TUMOR MODELS, BY REGION, 2023–2030 (USD MILLION)
TABLE 146
GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR OTHER TUMOR MODELS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 147
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 148
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PRECLINICAL RESEARCH, BY REGION, 2023–2030 (USD MILLION)
TABLE 149
NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PRECLINICAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 150
EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PRECLINICAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 151
ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PRECLINICAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 152
LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PRECLINICAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 153
MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PRECLINICAL RESEARCH, BY REGION, 2023–2030 (USD MILLION)
TABLE 154
GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PRECLINICAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 155
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOMARKER ANALYSIS, BY REGION, 2023–2030 (USD MILLION)
TABLE 156
NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 157
EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 158
ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 159
LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 160
MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOMARKER ANALYSIS, BY REGION, 2023–2030 (USD MILLION)
TABLE 161
GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 162
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR TRANSLATIONAL RESEARCH, BY REGION, 2023–2030 (USD MILLION)
TABLE 163
NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR TRANSLATIONAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 164
EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR TRANSLATIONAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 165
ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR TRANSLATIONAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 166
LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR TRANSLATIONAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 167
MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR TRANSLATIONAL RESEARCH, BY REGION, 2023–2030 (USD MILLION)
TABLE 168
GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR TRANSLATIONAL RESEARCH, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 169
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOBANKING, BY REGION, 2023–2030 (USD MILLION)
TABLE 170
NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOBANKING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 171
EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOBANKING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 172
ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOBANKING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 173
LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOBANKING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 174
MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOBANKING, BY REGION, 2023–2030 (USD MILLION)
TABLE 175
GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR BIOBANKING, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 176
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 177
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 178
NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 179
EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 180
ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 181
LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 182
MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 183
GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 184
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR CROS & CDMOS, BY REGION, 2023–2030 (USD MILLION)
TABLE 185
NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 186
EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 187
ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 188
LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 189
MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR CROS & CDMOS, BY REGION, 2023–2030 (USD MILLION)
TABLE 190
GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 191
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)
TABLE 192
NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 193
EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 194
ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 195
LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 196
MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)
TABLE 197
GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 198
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 199
NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 200
NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)
TABLE 201
NORTH AMERICA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 202
NORTH AMERICA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 203
NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION)
TABLE 204
NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION)
TABLE 205
NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 206
NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 207
US: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)
TABLE 208
US: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 209
US: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 210
US: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION)
TABLE 211
US: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION)
TABLE 212
US: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 213
US: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 214
CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)
TABLE 215
CANADA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 216
CANADA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 217
CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION)
TABLE 218
CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION)
TABLE 219
CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 220
CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 221
EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 222
EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)
TABLE 223
EUROPE: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 224
EUROPE: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 225
EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION)
TABLE 226
EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION)
TABLE 227
EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 228
EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 229
GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)
TABLE 230
GERMANY: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 231
GERMANY: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 232
GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION)
TABLE 233
GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION)
TABLE 234
GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 235
GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 236
UK: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)
TABLE 237
UK: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 238
UK: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 239
UK: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION)
TABLE 240
UK: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION)
TABLE 241
UK: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 242
UK: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 243
FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)
TABLE 244
FRANCE: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 245
FRANCE: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 246
FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION)
TABLE 247
FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION)
TABLE 248
FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 249
FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 250
ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)
TABLE 251
ITALY: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 252
ITALY: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 253
ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION)
TABLE 254
ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION)
TABLE 255
ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 256
ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 257
SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)
TABLE 258
SPAIN: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 259
SPAIN: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 260
SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION)
TABLE 261
SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION)
TABLE 262
SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 263
SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 264
REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)
TABLE 265
REST OF EUROPE: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 266
REST OF EUROPE: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 267
REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION)
TABLE 268
REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION)
TABLE 269
REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 270
REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 271
ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)
TABLE 272
ASIA PACIFIC: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 273
ASIA PACIFIC: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 274
ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION)
TABLE 275
ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS, BY TUMOR TYPE, 2023–2030 (USD MILLION)
TABLE 276
ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 277
ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 278
CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)
TABLE 279
CHINA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 280
CHINA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 281
CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION)
TABLE 282
CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION)
TABLE 283
CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 284
CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 285
JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)
TABLE 286
JAPAN: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 287
JAPAN: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 288
JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION)
TABLE 289
JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION)
TABLE 290
JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 291
JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 292
INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)
TABLE 293
INDIA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 294
INDIA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 295
INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION)
TABLE 296
INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION)
TABLE 297
INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 298
INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 299
AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)
TABLE 300
AUSTRALIA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 301
AUSTRALIA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 302
AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION)
TABLE 303
AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION)
TABLE 304
AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 305
AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 306
SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)
TABLE 307
SOUTH KOREA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 308
SOUTH KOREA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 309
SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION)
TABLE 310
SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION)
TABLE 311
SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 312
SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 313
REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)
TABLE 314
REST OF ASIA PACIFIC: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 315
REST OF ASIA PACIFIC: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 316
REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION)
TABLE 317
REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION)
TABLE 318
REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 319
REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 320
LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 321
LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)
TABLE 322
LATIN AMERICA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 323
LATIN AMERICA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 324
LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION)
TABLE 325
LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION)
TABLE 326
LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 327
LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 328
BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)
TABLE 329
BRAZIL: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 330
BRAZIL: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 331
BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION)
TABLE 332
BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION)
TABLE 333
BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 334
BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 335
MEXICO: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)
TABLE 336
MEXICO: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 337
MEXICO: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 338
MEXICO: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION)
TABLE 339
MEXICO: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION)
TABLE 340
MEXICO: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 341
MEXICO: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 342
REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)
TABLE 343
REST OF LATIN AMERICA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 344
REST OF LATIN AMERICA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 345
REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION)
TABLE 346
REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION)
TABLE 347
REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 348
REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 349
MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY REGION, 2023–2030 (USD MILLION)
TABLE 350
MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)
TABLE 351
MIDDLE EAST: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 352
MIDDLE EAST: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 353
MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION)
TABLE 354
MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION)
TABLE 355
MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 356
MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 357
GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 358
GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)
TABLE 359
GCC COUNTRIES: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 360
GCC COUNTRIES: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 361
GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION)
TABLE 362
GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION)
TABLE 363
GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 364
GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 365
KINGDOM OF SAUDI ARABIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)
TABLE 366
KINGDOM OF SAUDI ARABIA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 367
KINGDOM OF SAUDI ARABIA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 368
KINGDOM OF SAUDI ARABIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION)
TABLE 369
KINGDOM OF SAUDI ARABIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION)
TABLE 370
KINGDOM OF SAUDI ARABIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 371
KINGDOM OF SAUDI ARABIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 372
UAE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)
TABLE 373
UAE: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 374
UAE: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 375
UAE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION)
TABLE 376
UAE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION)
TABLE 377
UAE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 378
UAE: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 379
REST OF GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)
TABLE 380
REST OF GCC COUNTRIES: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 381
REST OF GCC COUNTRIES: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 382
REST OF GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION)
TABLE 383
REST OF GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION)
TABLE 384
REST OF GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 385
REST OF GCC COUNTRIES: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 386
REST OF MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)
TABLE 387
REST OF MIDDLE EAST: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 388
REST OF MIDDLE EAST: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 389
REST OF MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION)
TABLE 390
REST OF MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION)
TABLE 391
REST OF MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 392
REST OF MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 393
AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2023–2030 (USD MILLION)
TABLE 394
AFRICA: PDX MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 395
AFRICA: PDX SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)
TABLE 396
AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2023–2030 (USD MILLION)
TABLE 397
AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2023–2030 (USD MILLION)
TABLE 398
AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
TABLE 399
AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030 (USD MILLION)
TABLE 400
STRATEGIES ADOPTED BY KEY PLAYERS IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, 2022−2025
TABLE 401
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: DEGREE OF COMPETITION
TABLE 402
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: REGION FOOTPRINT
TABLE 403
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: MODEL TYPE & SERVICE FOOTPRINT
TABLE 404
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: TUMOR TYPE FOOTPRINT
TABLE 405
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: IMPLANTATION METHOD FOOTPRINT
TABLE 406
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
TABLE 407
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY MODEL TYPE & SERVICE AND REGION
TABLE 408
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: DEALS, JANUARY 2022− OCTOBER 2025
TABLE 409
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: EXPANSIONS, JANUARY 2022− OCTOBER 2025
TABLE 410
CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
TABLE 411
CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES OFFERED
TABLE 412
CHARLES RIVER LABORATORIES: DEALS, JANUARY 2022–OCTOBER 2025
TABLE 413
CHARLES RIVER LABORATORIES: EXPANSIONS, JANUARY 2022–OCTOBER 2025
TABLE 414
THE JACKSON LABORATORY: COMPANY OVERVIEW
TABLE 415
THE JACKSON LABORATORY: PRODUCTS/SERVICES OFFERED
TABLE 416
THE JACKSON LABORATORY: DEALS, JANUARY 2022–OCTOBER 2025
TABLE 417
THE JACKSON LABORATORY: EXPANSIONS, JANUARY 2022–OCTOBER 2025
TABLE 418
INOTIV: COMPANY OVERVIEW
TABLE 419
INOTIV: PRODUCTS/SERVICES OFFERED
TABLE 420
INOTIV: EXPANSIONS, JANUARY 2022–OCTOBER 2025
TABLE 421
JSR CORPORATION: COMPANY OVERVIEW
TABLE 422
JSR CORPORATION: PRODUCTS/SERVICES OFFERED
TABLE 423
JSR CORPORATION: DEALS, JANUARY 2022–OCTOBER 2025
TABLE 424
JSR CORPORATION: EXPANSIONS, JANUARY 2022–OCTOBER 2025
TABLE 425
GENOWAY: COMPANY OVERVIEW
TABLE 426
GENOWAY: PRODUCTS/SERVICES OFFERED
TABLE 427
WUXI APPTEC + WUXI BIOLOGICS: COMPANY OVERVIEW
TABLE 428
WUXI APPTEC + WUXI BIOLOGICS: PRODUCTS/SERVICES OFFERED
TABLE 429
WUXI APPTEC + WUXI BIOLOGICS: DEALS, JANUARY 2022–OCTOBER 2025
TABLE 430
WUXI APPTEC + WUXI BIOLOGICS: EXPANSIONS, JANUARY 2022–OCTOBER 2025
TABLE 431
BIOCYTOGEN PHARMACEUTICALS CO., LTD.: COMPANY OVERVIEW
TABLE 432
BIOCYTOGEN PHARMACEUTICALS CO., LTD.: PRODUCTS/SERVICES OFFERED
TABLE 433
BIOCYTOGEN PHARMACEUTICALS CO., LTD.: PRODUCT/SERVICE UPGRADES, JANUARY 2022–OCTOBER 2025
TABLE 434
BIOCYTOGEN PHARMACEUTICALS CO., LTD.: EXPANSIONS, JANUARY 2022–OCTOBER 2025
TABLE 435
TACONIC BIOSCIENCES, INC.: COMPANY OVERVIEW
TABLE 436
TACONIC BIOSCIENCES, INC.: PRODUCTS/SERVICES OFFERED
TABLE 437
TACONIC BIOSCIENCES, INC.: PRODUCT/SERVICE LAUNCHES, JANUARY 2022–OCTOBER 2025
TABLE 438
TACONIC BIOSCIENCES, INC.: DEALS, JANUARY 2022–OCTOBER 2025
TABLE 439
TACONIC BIOSCIENCES, INC.: EXPANSIONS, JANUARY 2022–OCTOBER 2025
TABLE 440
ONCODESIGN SERVICES (ONCODESIGN PRECISION MEDICINE): COMPANY OVERVIEW
TABLE 441
ONCODESIGN SERVICES (ONCODESIGN PRECISION MEDICINE): PRODUCTS/SERVICES OFFERED
TABLE 442
CHAMPIONS ONCOLOGY, INC.: COMPANY OVERVIEW
TABLE 443
CHAMPIONS ONCOLOGY, INC.: PRODUCTS/SERVICES OFFERED
TABLE 444
CHAMPIONS ONCOLOGY, INC.: DEALS, JANUARY 2022–OCTOBER 2025
TABLE 445
PHARMARON: COMPANY OVERVIEW
TABLE 446
PHARMARON: PRODUCTS/SERVICES OFFERED
TABLE 447
SYNGENE INTERNATIONAL LIMITED: COMPANY OVERVIEW
TABLE 448
SYNGENE INTERNATIONAL LIMITED: PRODUCTS/SERVICES OFFERED
TABLE 449
LABCORP: COMPANY OVERVIEW
TABLE 450
LABCORP: PRODUCTS/SERVICES OFFERED
TABLE 451
EUROFINS SCIENTIFIC: COMPANY OVERVIEW
TABLE 452
EUROFINS SCIENTIFIC: PRODUCTS/SERVICES OFFERED
TABLE 453
VITALSTAR BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW
TABLE 454
VITALSTAR BIOTECHNOLOGY CO., LTD.: PRODUCTS/SERVICES OFFERED
TABLE 455
CREATIVE ANIMODEL: COMPANY OVERVIEW
TABLE 456
JOINN LABORATORIES (CHINA) CO., LTD.: COMPANY OVERVIEW
TABLE 457
CREATIVE BIOLABS: COMPANY OVERVIEW
TABLE 458
ARAGEN LIFE SCIENCES LTD.: BUSINESS OVERVIEW
TABLE 459
PHARMATEST: BUSINESS OVERVIEW
TABLE 460
LIDE SHANGHAI BIOTECH CO., LTD.: COMPANY OVERVIEW
TABLE 461
CERTIS ONCOLOGY SOLUTIONS: COMPANY OVERVIEW
TABLE 462
INNOSER: COMPANY OVERVIEW
TABLE 463
SHANGHAI CHEMPARTNER: COMPANY OVERVIEW
TABLE 464
IVRS AB: COMPANY OVERVIEW
TABLE 465
PATIENT-DERIVED XENOGRAFTS (PDX) MODELS MARKET: IMPACT ANALYSIS
TABLE 466
PATIENT-DERIVED XENOGRAFTS (PDX) MODELS MARKET: RISK ANALYSIS
LIST OF FIGURES
FIGURE 1
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: YEARS CONSIDERED
FIGURE 3
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY MODEL TYPE & SERVICE, 2025 VS. 2030 (USD MILLION)
FIGURE 4
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY IMPLANTATION METHOD, 2025 VS. 2030 (USD MILLION)
FIGURE 5
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY TUMOR TYPE, 2025 VS. 2030 (USD MILLION)
FIGURE 6
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
FIGURE 7
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
FIGURE 8
GROWING DEMAND FOR IMMUNO-ONCOLOGY AND COMPLEX BIOLOGICS TO DRIVE MARKET
FIGURE 9
US AND PDX MODELS COMMANDED LARGEST MARKET SHARE IN 2024
FIGURE 10
CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 11
SUBCUTANEOUS IMPLANTATION TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 12
MODEL CREATION & EXPANSION ACCOUNTED FOR LARGEST MARKET MARKET SHARE IN 2024
FIGURE 13
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 14
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: PORTER’S FIVE FORCES
FIGURE 15
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: ECOSYSTEM ANALYSIS
FIGURE 16
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: VALUE CHAIN ANALYSIS
FIGURE 17
AVERAGE SELLING PRICE TREND OF MODEL TYPES, BY KEY PLAYER, 2022–2024 (USD)
FIGURE 18
AVERAGE SELLING PRICE OF PATIENT-DERIVED XENOGRAFT (PDX) MODEL TYPES, BY REGION, 2024 (USD)
FIGURE 19
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
FIGURE 20
PATENT APPLICATIONS IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, JANUARY 2014–DECEMBER 2024
FIGURE 21
NUMBER OF DEALS AND FUNDING IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, 2022–2025 (USD MILLION)
FIGURE 22
TOP USE CASES IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET
FIGURE 23
INFLUENCE OF KEY STAKEHOLDERS ON DECISION-MAKING FOR PATIENT-DERIVED XENOGRAFT (PDX) MODELS
FIGURE 24
BUYING EVALUATION CRITERIA FOR PATIENT-DERIVED XENOGRAFT (PDX) MODELS
FIGURE 25
NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET SNAPSHOT
FIGURE 26
ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET SNAPSHOT
FIGURE 27
REVENUE ANALYSIS FOR KEY PLAYERS IN PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, 2022–2024 (USD MILLION)
FIGURE 28
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET SHARE ANALYSIS OF KEY PLAYERS (2024)
FIGURE 29
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS) 2024,
FIGURE 30
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: COMPANY FOOTPRINT
FIGURE 31
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 32
EV/EBITDA OF KEY VENDORS
FIGURE 33
YEAR-TO-DATE (YTD) PRICE, TOTAL RETURN, AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 34
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 35
CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
FIGURE 38
JSR CORPORATION: COMPANY SNAPSHOT
FIGURE 39
GENOWAY: COMPANY SNAPSHOT
FIGURE 40
WUXI APPTEC + WUXI BIOLOGICS: COMPANY SNAPSHOT
FIGURE 41
BIOCYTOGEN PHARMACEUTICALS CO., LTD.: COMPANY SNAPSHOT
FIGURE 42
CHAMPIONS ONCOLOGY, INC.: COMPANY SNAPSHOT
FIGURE 43
PHARMARON: COMPANY SNAPSHOT
FIGURE 44
SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT
FIGURE 45
LABCORP: COMPANY SNAPSHOT
FIGURE 46
EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
FIGURE 47
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: RESEARCH DESIGN
FIGURE 48
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: BREAKDOWN OF PRIMARIES (SUPPLY- AND DEMAND-SIDE PARTICIPANTS)
FIGURE 49
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
FIGURE 50
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (2024)
FIGURE 51
PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET: ILLUSTRATIVE REVENUE ANALYSIS OF CHARLES RIVER LABORATORIES (2024)
FIGURE 52
PATIENT-DERIVED XENOGRAFTS (PDX) MODELS MARKET SIZE VALIDATION FROM PRIMARY SOURCES
FIGURE 53
PATIENT-DERIVED XENOGRAFTS (PDX) MODELS MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 54
PATIENT-DERIVED XENOGRAFTS (PDX) MODELS MARKET: CAGR PROJECTIONS
FIGURE 55
PATIENT-DERIVED XENOGRAFTS (PDX) MODELS MARKET: DATA TRIANGULATION METHODOLOGY
Methodology
This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global PDX model market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.
Secondary Research
Secondary research was primarily used to identify and collect information for the comprehensive technical, market-oriented, and commercial study of the PDX model market. The secondary sources used for this study include World Health Organization (WHO), American Association for Cancer Research, American Association for Laboratory Animal Science, EurOPDX, European Animal Research Association, European Society for Medical Oncology, European Association for Cancer Research, Federation for Laboratory of Cell Therapy, International Journal of Non-Communicable Diseases, European Medicines Agency (EMA), Alliance for Regenerative Medicine (ARM); ACS Journals; Corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.
Secondary data were collected and analyzed to determine the overall size of the global PDX model market, which was subsequently validated through primary research. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate & validate the total size of the PDX model market. These methods were also used extensively to estimate the size of various market segments.
Data Triangulation
After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.
Market Definition
Patient-derived xenografts (PDXs) are models of cancer where the tissue or cells from a patient’s tumor are implanted into an immunodeficient or humanized mouse. These models have been used to grow cancer tissues after they were removed from a patient. The PDX model is an important tool for cancer research. It is used to study the biology of cancer, test the efficacy of new therapies, and predict the response to therapy in individual patients.
The study offers an in-depth analysis of the PDX model market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key PDX model product providers.
Stakeholders
- Pharmaceutical & biotechnology companies
- Contract research organizations (CROs)
- Academic & research institutes
- Preclinical and translational research centers
- Life science companies
- Regulatory bodies
- Contract development and manufacturing organizations (CDMOs)
- Cancer research consortia & foundations
- Venture capitalists & strategic investors
- Government associations
- Medical institutions & universities
- Hospitals & clinics
Report Objectives
- To define, describe, and forecast the PDX model market based on implantation method, type, tumor type, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall PDX model market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the PDX model market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as acquisitions, expansions, agreements, partnerships, and collaborations in the PDX model market
- To benchmark players within the PDX model market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Patient Derived Xenografts/PDX Models Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Before You Go
Expand Beyond Patient Derived Xenografts/PDX Models Market
Explore the top 20 industries influencing your market growth
Human and AI Powered Market Intelligence
Find Untapped Markets
Growth opportunities and latent adjacency in Patient Derived Xenografts/PDX Models Market